Constitutive Activity at the α 1 ‐Adrenoceptors: Past and Future Implications

Author(s):  
Susanna Cotecchia ◽  
Francesca Fanelli ◽  
Alexander Scheer ◽  
Tommaso Costa
2013 ◽  
Author(s):  
Yves Louis Mear ◽  
Xavier Come Donato ◽  
Marie Pierre Blanchard ◽  
Celine Defilles ◽  
Christophe Lisbonis ◽  
...  

Author(s):  
Qinying Wang ◽  
Xiaoxu Dong ◽  
Tingting Hu ◽  
Chao Qu ◽  
Jing Lu ◽  
...  

2012 ◽  
Vol 8 (4) ◽  
pp. 677-692 ◽  
Author(s):  
Edin Ibrisimovic ◽  
Helmut Drobny ◽  
Qiong Yang ◽  
Thomas Höfer ◽  
Stefan Boehm ◽  
...  

2006 ◽  
Vol 34 (6) ◽  
pp. 1303-1306 ◽  
Author(s):  
M.A. Pagano ◽  
L. Cesaro ◽  
F. Meggio ◽  
L.A. Pinna

The acronym CK2 (derived from the misnomer ‘casein kinase’ 2) denotes one of the most pleiotropic members of the eukaryotic protein kinase superfamily, characterized by an acidic consensus sequence in which a carboxylic acid (or pre-phosphorylated) side chain at position n+3 relative to the target serine/threonine residue plays a crucial role. The latest repertoire of CK2 substrates includes approx. 300 proteins, but the analysis of available phosphopeptide databases from different sources suggests that CK2 alone may be responsible for the generation of a much larger proportion (10–20%) of the eukaryotic phosphoproteome. Although for the time being CK2 is not included among protein kinases whose inhibitors are in clinical practice or in advanced clinical trials, evidence is accumulating that elevated CK2 constitutive activity co-operates to induce a number of pathological conditions, including cancer, infectious diseases, neurodegeneration and cardiovascular pathologies. The development and usage of cell-permeant, selective inhibitors discloses a scenario whereby CK2 plays a global anti-apoptotic role, which under special circumstances may lead to untimely and pathogenic cell survival.


2001 ◽  
Vol 277 (4) ◽  
pp. 2534-2546 ◽  
Author(s):  
Evgeni G. Ponimaskin ◽  
Martin Heine ◽  
Lara Joubert ◽  
Michèle Sebben ◽  
Ulf Bickmeyer ◽  
...  

2004 ◽  
Vol 279 (51) ◽  
pp. 53806-53817 ◽  
Author(s):  
Birgitte Holst ◽  
Nicholas D. Holliday ◽  
Anders Bach ◽  
Christian E. Elling ◽  
Helen M. Cox ◽  
...  

PLoS ONE ◽  
2015 ◽  
Vol 10 (9) ◽  
pp. e0138463 ◽  
Author(s):  
Adam L. Martin ◽  
Michael A. Steurer ◽  
Robert S. Aronstam

2014 ◽  
Vol 99 (12) ◽  
pp. E2463-E2471 ◽  
Author(s):  
Yves Mear ◽  
Marie-Pierre Blanchard ◽  
Céline Defilles ◽  
Thierry Brue ◽  
Dominique Figarella-Branger ◽  
...  

Context: The ghrelin receptor GHS-R1a is highly expressed in human somatotroph adenomas and exhibits unusually high basal signaling activity. In humans, the suppression of this constitutive activity by mutation induces a short stature. Objective: Using a GHS-R1a inverse agonist, modified substance P (MSP), we explored the role of GHS-R1a constitutive activity in GH hypersecretion from somatotroph adenomas and as a putative therapeutic target. Design: The effects of MSP were assessed on GH secretion from 19 human somatotroph tumors in vitro. Moreover, these effects were compared with those of octreotide (somatostatin receptor subtype 2 [sst2] agonist) and with the combination of both drugs. Expression and localization of GHS-R1a and sst2 were studied. Results: For all tumors, MSP inhibited GH secretion in a dose-dependent manner from 13 to 64%. Moreover, MSP enhanced octreotide-induced GH inhibition. For five tumors, the effects of combined MSP plus octreotide treatment were significantly higher than the sum of effects of each drug alone. MSP increased the membrane localization of GHS-R1a and of microdomains colocalizing sst2-GHS-R1a, highlighting the cooperation between the two drugs. Conclusions: The GHS-R1a inverse agonist could open new therapeutic options for acromegalic patients, particularly patients partially sensitive to octreotide whose GH secretion is not completely controlled by the sst2 agonist.


2017 ◽  
Vol 12 (8) ◽  
pp. e1356533 ◽  
Author(s):  
Julien Lang ◽  
Baptiste Genot ◽  
Heribert Hirt ◽  
Jean Colcombet

Sign in / Sign up

Export Citation Format

Share Document